Cargando…
Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies
Intravenous immunoglobulin (IVIG) is a potential therapy for chronic inflammatory demyelinating polyneuropathy (CIDP). To investigate the efficacy and safety of the IVIG IgPro10 (Privigen) for treatment of CIDP, results from Privigen Impact on Mobility and Autonomy (PRIMA), a prospective, open‐label...
Autores principales: | Merkies, Ingemar S.J., van Schaik, Ivo N., Léger, Jean‐Marc, Bril, Vera, van Geloven, Nan, Hartung, Hans‐Peter, Lewis, Richard A., Sobue, Gen, Lawo, John‐Philip, Durn, Billie L., Cornblath, David R., De Bleecker, Jan L., Sommer, Claudia, Robberecht, Wim, Saarela, Mika, Kamienowski, Jerzy, Stelmasiak, Zbigniew, Tackenberg, Björn, Mielke, Orell |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wiley Periodicals, Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594229/ https://www.ncbi.nlm.nih.gov/pubmed/30672091 http://dx.doi.org/10.1111/jns.12302 |
Ejemplares similares
-
Minimum clinically important difference analysis confirms the efficacy of IgPro10 in CIDP: the PRIMA trial
por: Merkies, Ingemar S. J., et al.
Publicado: (2017) -
Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study
por: van Schaik, Ivo N., et al.
Publicado: (2019) -
Efficacy and safety of Privigen® in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study)
por: Léger, Jean-Marc, et al.
Publicado: (2013) -
Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre‐randomization phase of the Polyneuropathy And Treatment with Hizentra study
por: Mielke, Orell, et al.
Publicado: (2019) -
Placebo effect in chronic inflammatory demyelinating polyneuropathy: The PATH study and a systematic review
por: Lewis, Richard A., et al.
Publicado: (2020)